Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.

View in: PubMed

subject areas

Adjuvants, Immunologic
Administration, Intravesical
Antineoplastic Agents
BCG Vaccine
Female
Humans
Male
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Prospective Studies
Urinary Bladder Neoplasms

authors with profiles

Michael S Cookson